Moderna (MRNA) Jumps 8.8% on COVID-19 Support from Medical Organizations

Moderna, Inc. (NASDAQ:MRNA) is one of These 10 Stocks Are Making Big Moves.

Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed against Health Secretary Robert F. Kennedy Jr. over policies on COVID-19 vaccines.

On Monday, six medical organizations sued Kennedy and the Department of Health and Human Services over the agency’s decision to limit vaccine access. The plaintiffs sought to restore the COVID-19 vaccine to the list of recommended immunizations for healthy children and pregnant women.

The plaintiffs include the American Public Health Association, the American Academy of Pediatrics, the Infectious Diseases Society of America, the American College of Physicians, the Society for Maternal-Fetal Medicine and the Massachusetts Public Health Alliance.

“The secretary’s intentions are clear. He (Kennedy) aims to destroy vaccines,” said Richard Hughes IV, a lawyer who teaches vaccine law at George Washington University, who is leading the effort.

The lawsuit was viewed as a tailwind for Moderna, Inc. (NASDAQ:MRNA), one of the few pharmaceutical companies that successfully developed its own COVID-19 vaccine during the pandemic.

While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.